Kosmonova buran
Top-News
VERNALIS :::oohhoooooo
Beiträge:
48
Zugriffe: 11.838 / Heute: 1
Zugriffe: 11.838 / Heute: 1
|
| 22 Beiträge ausgeblendet. |
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +48,05%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +46,01%
SPDR S&P U.S. Consumer Discretionary Select Sector UCITS ETF
Perf. 12M: +42,22%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +41,55%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +41,01%
und wenn die Bläserinnen die Verglockten tuten und blasen ..und die Engleins in Chören die Lieders lassen erdröhnen mit froher Schall im eisigen Weihnachtswinde ..und ich das buran mittem Paster den Turm hinauf die Glocke lassen schlagen die da heisst die dicke Sieglinde ..ja dann iss stille Nacht ..wenn die Bläserinnen nicht mehr die Tuten blasen und Englein stumm verchören geht's im Schnefall nach hause hinterm Ofen ..zu jener seiner geliebten holden der Weihnachtsfrommen Schönen
buran & VERNALIS,Die Börsen Weihnacht 2013 Die Verchörten Bläserinnen Der Ticker All Der Schönen
..SK 0,395 € SKP -2,47 Pott +27,83% ,GrB
buran & VERNALIS,Die Börsen Weihnacht 2013 Die Verchörten Bläserinnen Der Ticker All Der Schönen
..SK 0,395 € SKP -2,47 Pott +27,83% ,GrB
:::::::::::::::::::::::: 0,475 € +14,18% +0,059 €
Stuttgart, 15.01.14::::::::: Schlampagne für ALLE
buran & VERNALIS :::oohhoooooo
Stuttgart, 15.01.14::::::::: Schlampagne für ALLE
buran & VERNALIS :::oohhoooooo
Datum Erster Hoch Tief Schluss Stücke Volumen
15.01.14 0,475 0,475§0,475 0,475 € 2.000 950
14.01.14 0,42 0,42§0,416 0,416 € 1.574 655
GrB
15.01.14 0,475 0,475§0,475 0,475 € 2.000 950
14.01.14 0,42 0,42§0,416 0,416 € 1.574 655
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
16.01.14 0,461 0,461§0,46 0,46 € 2.300 1.058
GrB
16.01.14 0,461 0,461§0,46 0,46 € 2.300 1.058
GrB
Preis pro Anteilsschein 0,50 € Schleife 4.000 spread 11,11% buran und MfG und tau
Datum Erster Hoch Tief Schluss Stücke Volumen
31.01.14 0,39 0,425§0,39 0,425 € 5.000 2.125
GrB
31.01.14 0,39 0,425§0,39 0,425 € 5.000 2.125
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
30.01.14 0,372 0,372§0,365 0,365 € 7 3
buran und MfG und danke und SCHÖN
30.01.14 0,372 0,372§0,365 0,365 € 7 3
buran und MfG und danke und SCHÖN
VERNALIS PLC ORD Aktie
WKN: A0RM65 ISIN: GB00B3Y5L754 Symbol: VNLPF Typ: Aktie
SK 0,395 € SKP -3,19 Pott +27,83%
buran und MfG und danke und VERNALIS :::oohhoooooo
WKN: A0RM65 ISIN: GB00B3Y5L754 Symbol: VNLPF Typ: Aktie
SK 0,395 € SKP -3,19 Pott +27,83%
buran und MfG und danke und VERNALIS :::oohhoooooo
Preis pro Anteil 0,46 € Schleife 11.079 spread 7,23% buran und MfG und schick Likörchen
Preis pro Anteil 0,455 € Schleife 2.198 spread 10,44% buran und MfG und tau
SK 0,366 € SKP +0,00 Pott +18,45% ,GrB
..ät jibt nur ein Rudi Völlaaaaaaaaaaaaaa ..::hopshopshopshops HALLO
..ät jibt nur ein Rudi Völlaaaaaaaaaaaaaa ..::hopshopshopshops HALLO
(CCP-08) Achieves Proof-of-Concept
13:05 22.07.14
PR Newswire
MONMOUTH JUNCTION, N.J., July 22, 2014
MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their US prescription cough cold collaboration. Under this collaboration, POC requires the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. As a result of achieving POC, Vernalis will make a milestone payment to Tris.
Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+™ based extended release liquid equivalents to existing immediate release prescription cough/cold treatments. The financial terms of this licensing deal are not disclosed.
Ian Garland, CEO of Vernalis commented "Three of our five cough cold programmes in our collaboration with Tris have now achieved proof-of-concept and for the most advanced of those programmes (Tuzistra™ XR) an NDA has already been submitted to the FDA. We are delighted with the momentum building in our Tris collaboration and are looking forward to continuing success over the remainder of the year".
Ketan Mehta, CEO of Tris commented "This is an exciting time for both our companies with the continuing progress of the prescription cough cold portfolio and we look forward to the further success of our partnership with Vernalis."
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A.
For more information, please visit www.trispharma.com.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
SOURCE Tris Pharma, Inc.
Quelle: PR Newswire
13:05 22.07.14
PR Newswire
MONMOUTH JUNCTION, N.J., July 22, 2014
MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their US prescription cough cold collaboration. Under this collaboration, POC requires the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. As a result of achieving POC, Vernalis will make a milestone payment to Tris.
Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+™ based extended release liquid equivalents to existing immediate release prescription cough/cold treatments. The financial terms of this licensing deal are not disclosed.
Ian Garland, CEO of Vernalis commented "Three of our five cough cold programmes in our collaboration with Tris have now achieved proof-of-concept and for the most advanced of those programmes (Tuzistra™ XR) an NDA has already been submitted to the FDA. We are delighted with the momentum building in our Tris collaboration and are looking forward to continuing success over the remainder of the year".
Ketan Mehta, CEO of Tris commented "This is an exciting time for both our companies with the continuing progress of the prescription cough cold portfolio and we look forward to the further success of our partnership with Vernalis."
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A.
For more information, please visit www.trispharma.com.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
SOURCE Tris Pharma, Inc.
Quelle: PR Newswire
Datum Erster Hoch Tief Schluss Stücke Volumen
19.09.14 0,57 0,57§0,57 0,57 € 200 114
buran & Tante Tradegate
19.09.14 0,57 0,57§0,57 0,57 € 200 114
buran & Tante Tradegate
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
Teil des Rechenschafts- und Halbjahresberichts, aus dem Aufteilung und Veränderung des Fondsvermögens hervorgehen. http://www.ariva.de/extras/lexikon.m?begriff=Vermoegensaufstellung
::::::::::::::::::: 1,031 € +0,68% +0,007 €
Frankfurt, 31.07.15 ,GrB
Frankfurt, 31.07.15 ,GrB
One of the UK’s leading commercial stage pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses and our own research activities.
The strategy is to:
Build a profitable and cash generative business
Develop and commercialise low development-risk late-stage products for unmet medical needs in the US
Partner all of our NCE drug candidates
Leverage our structure- and fragment-based drug discovery expertise via collaborations with leading pharmaceutical companies www.vernalis.com/about-us
The strategy is to:
Build a profitable and cash generative business
Develop and commercialise low development-risk late-stage products for unmet medical needs in the US
Partner all of our NCE drug candidates
Leverage our structure- and fragment-based drug discovery expertise via collaborations with leading pharmaceutical companies www.vernalis.com/about-us
, self-sustaining pharmaceutical company. Our strategy to achieve this vision takes the best of what the Company already has and supplements it through in-licensing and acquisition. We are following a three-tier strategy to achieve these goals. www.vernalis.com/about-us/vision-and-strategy
2017
Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017. www.vernalis.com/
Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017. www.vernalis.com/
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Vernalis Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 47 | VERNALIS :::oohhoooooo | buran | buran | 25.04.21 00:42 |
